Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CalciMedica Inc. (CALC : NSDQ)

• Company Description    CalciMedica Inc. is a clinical-stage biopharmaceutical company. It focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica Inc. is based in LA JOLLA, Calif. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $3.04 Daily Weekly Monthly 20 Day Moving Average: 29,856 shares Shares Outstanding: 14.40 (millions) Market Capitalization: $43.78 (millions) Beta: 1.37 52 Week High: $4.26 52 Week Low: $1.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.95% -6.47% 12 Week 4.47% 0.14% Year To Date -14.12% -24.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 505 Coast Boulevard South Suite 307 - La Jolla,CA 92037 USA ph: 858-952-5500 fax: - calcimedica@argotpartners.com http://www.calcimedica.com

• General Corporate Information    Officers A. Rachel Leheny - Chief Executive Officer and Director Robert N. Wilson - Chairman Stephen Bardin - Chief Financial Officer Alan Glicklich - Director Frederic Guerard - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 38942Q202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 14.40 Most Recent Split Date: 3.00 (0.07:1) Beta: 1.37 Market Capitalization: $43.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 23.08% vs. Previous Quarter: -11.11% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -206.51 03/31/25 - -171.81 ROA 09/30/25 - - 06/30/25 - -103.81 03/31/25 - -100.43 Current Ratio 09/30/25 - - 06/30/25 - 5.45 03/31/25 - 5.66 Quick Ratio 09/30/25 - - 06/30/25 - 5.45 03/31/25 - 5.66 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.44 03/31/25 - 0.78 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 1.39 03/31/25 - 0.79 Debt-to-Capital 09/30/25 - - 06/30/25 - 58.21 03/31/25 - 44.13

Powered by Zacks Investment Research ©